Mannitol Adverse Reaction
Conditions
Brief summary
Group 1 will include 20 patients aged 18 years and over, American Society of Anesthesiologist (ASA) II-III class, who will undergo supratentorial tumor surgery, and Group 2 will include 20 patients who will undergo pituitary surgery without mannitol. Total intravenous anesthesia (TIVA) will be adjusted to propofol 4 µg/dl and remifentanil 2-4 µg/dl with target-controlled infusion pumps. In the mannitol group, 2.5 ml/kg (0.5 g/kg) will be given to all patients 20 minutes after induction and the mannitol infusion will be adjusted to be 10 minutes.In Group 2, mannitol will not be used and 2.5 ml/kg isotonic will be administered in 10 minutes. Both blood and urine samples will take for measurement to propofol levels.
Detailed description
The participants will divide into the two groups. Group 1 will include 20 patients aged 18 years and over, American Society of Anesthesiologist (ASA) II-III class, who will undergo supratentorial tumor surgery, (Mannitol group) and Group 2 will include 20 patients who will undergo pituitary surgery without mannitol (Control Group). Total intravenous anesthesia (TIVA) will be adjusted to propofol 4 µg/dl and remifentanil 2-4 µg/dl with target-controlled infusion pumps. In the mannitol group, 2.5 ml/kg (0.5 g/kg) will be given to all patients 20 minutes after induction and the mannitol infusion will be adjusted to be 10 minutes.In Group 2, mannitol will not be used and 2.5 ml/kg isotonic will be administered in 10 minutes. Both blood and urine samples will take for measurement to propofol levels. Beside to standard monitoring invasive hemodynamic monitorization (cardiac output, cardiac index, stroke volume variability) and bispectral index will apply to the all participants.
Interventions
DRUGmannitol
2.5 mg/kg Mannitol will be given intravenously
OTHERSaline
2.5 ml/kg saline will be given as plasebo
Sponsors
Cukurova University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* American Society of Anesthesiologist (ASA) II participants * supratentorial tumor surgery * eligible for mannitol use * eligible for Total intravenous anesthesia (TIVA)
Exclusion criteria
* American Society of Anesthesiologist (ASA) III and upper * Chronic kidney failure * sepsis * multiorgan failure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum propofol levels | Blood samples will take at intraoperatif period during total intravenous anesthesia (TIVA). (Till the 100th minutes of anesthesia) | Blood samples will be taken during study and then propofol levels will measure at the end of study. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Urine propofol levels | The sample collection will continue till the 100th minutes of anesthesia (TIVA) | Urine samples will take during total intravenous anesthesia (TIVA). And then urine propofol levels will measure. |
Countries
Turkey (Türkiye)
Contacts
Primary ContactEbru Biricik
Outcome results
None listed